ResMed Inc.

NYSE:RMD Stock Report

Market Cap: US$33.8b

ResMed Past Earnings Performance

Past criteria checks 6/6

ResMed has been growing earnings at an average annual rate of 16.8%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 11.8% per year. ResMed's return on equity is 21.4%, and it has net margins of 23.1%.

Key information

16.8%

Earnings growth rate

16.3%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate11.8%
Return on equity21.4%
Net Margin23.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

ResMed: Solid Execution, Pricey Valuation

Nov 25

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08
ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13
ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

Compound Your Wealth With ResMed

Jul 04

Revenue & Expenses Breakdown

How ResMed makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:RMD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,8071,113933311
30 Jun 244,6851,021917308
31 Mar 244,584958916305
31 Dec 234,504890914304
30 Sep 234,375907903300
30 Jun 234,223898874288
31 Mar 234,016863826274
31 Dec 223,763809780264
30 Sep 223,624786755257
30 Jun 223,578779738254
31 Mar 223,539779726249
31 Dec 213,444522704238
30 Sep 213,349500688231
30 Jun 213,197475670225
31 Mar 213,091457654218
31 Dec 203,092699666213
30 Sep 203,028680668208
30 Jun 202,957622677202
31 Mar 202,892513683201
31 Dec 192,784455675197
30 Sep 192,699419665190
30 Jun 192,607405645181
31 Mar 192,525446630169
31 Dec 182,455450614159
30 Sep 182,405335604157
30 Jun 182,340316600155
31 Mar 182,273307591152
31 Dec 172,196285581150
30 Sep 172,125352569147
30 Jun 172,067342554144
31 Mar 172,029324532142
31 Dec 161,968327518135
30 Sep 161,893346496126
30 Jun 161,839352488119
31 Mar 161,773357481113
31 Dec 151,742357475112
30 Sep 151,710353479112
30 Jun 151,679353479115
31 Mar 151,641353478118
31 Dec 141,616352473121
30 Sep 141,578348466121
30 Jun 141,555345450118
31 Mar 141,554331443118
31 Dec 131,540325441119

Quality Earnings: RMD has high quality earnings.

Growing Profit Margin: RMD's current net profit margins (23.1%) are higher than last year (20.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RMD's earnings have grown by 16.8% per year over the past 5 years.

Accelerating Growth: RMD's earnings growth over the past year (22.8%) exceeds its 5-year average (16.8% per year).

Earnings vs Industry: RMD earnings growth over the past year (22.8%) exceeded the Medical Equipment industry 12.9%.

Return on Equity

High ROE: RMD's Return on Equity (21.4%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 07:35
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ResMed Inc. is covered by 57 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterANZ Equities Pty Limited
Russell WrightAPP Securities Pty Ltd.
David RescottBaird